AVROBIO (AVRO) Stock Price, News & Analysis

Company Overview

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.38 to $1.44
• 50-Day Range: $1.40 to $18.24
• 52-Week Range: $0.88 to $1.65
• Volume: 206,800 shs
• Average Volume: 269,831 shs
• Market Capitalization: $62.85 million
• P/E Ratio: 2.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVRO Stock Analysis - Frequently Asked Questions

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its earnings results on Thursday, November, 4th. The company reported ($9.00) earnings per share for the quarter, meeting the consensus estimate of ($9.00).

When did AVROBIO's stock split?

AVROBIO's stock reverse split before market open on Thursday, June 20th 2024. The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did AVROBIO IPO?

AVROBIO (AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 4/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AVRO
• CIK: 1681087
• Web: www.avrobio.com
• Phone: (617) 914-8420
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.69
• Trailing P/E Ratio: 2.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $12.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.52%
• Return on Assets: -47.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.17
• Quick Ratio: 26.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.13 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 44,890,000
• Free Float: 40,764,000
• Market Cap: $62.85 million
• Optionable: Optionable
• Beta: 1.23